ArticleGene therapy2003
Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases.
Article in Gene therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- Antigen identification and high-throughput interaction mapping by reprogramming viral entry.Nature methods · 2022Article
- Generation of a caged lentiviral vector through an unnatural amino acid for photo-switchable transduction.Nucleic acids research · 2019Article
- Physical, chemical, and synthetic virology: Reprogramming viruses as controllable nanodevices.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- Stimulus-responsive viral vectors for controlled delivery of therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- MicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response.Human gene therapy · 2014Article
- Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines.Journal of virology · 2014Article
- Current advances in retroviral gene therapy.Current gene therapy · 2011Review
- Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.Biochimica et biophysica acta · 2008Review
- Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue.Gene therapy · 2008Article
- Molecular engineering of viral gene delivery vehicles.Annual review of biomedical engineering · 2008Review
- Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth.Cancer gene therapy · 2005Article
- Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.Gene therapy · 2005Review
- Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells.Gene therapy · 2005Article
- Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.Cancer gene therapy · 2005Article
- Selection of functional human antibodies from retroviral display libraries.Nucleic acids research · 2005Article
- Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles.Journal of virology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protease-activatable retroviral vectors offer the possibility of targeted gene transfer into cancer cells expressing a unique set of proteases as, for example, the matrix metalloproteases (MMPs). However, it is difficult to predict which substrate sequence will be optimally cleaved by a given tumour cell type. Therefore, we developed a novel approach that allows the selection of MMP-activatable retroviruses from libraries of viruses displaying combinatorially diversified protease substrates. Starting from a virus harbouring a standard MMP-2 substrate motif, after only two consecutive cycles of diversification and in vivo selection, MMP-activatable viruses were recovered. Biochemical characterization of the selected viruses revealed that their linker peptides showed a considerably increased sensitivity for MMP-2 cleavage, and interestingly also improved the particle incorporation rate of the Env protein. Owing to the optimized linker peptide, the selected viruses exhibited a greatly enhanced spreading efficiency through human fibrosarcoma cells, while having retained the dependency on MMP activation. Moreover, cell entry efficiency and virus titres were considerably improved as compared to the parental virus displaying the standard MMP-2 substrate. The results presented imply that retroviral protease substrate libraries allow the definition of MMP substrate specificities under in vivo conditions as well as the generation of optimally adapted tumour-specific viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.